McFarlane equates the detailed planning of military operations—like establishing a field hospital—with creating a biotech strategic plan. Both require allocating people, time, and money with a clear, mission-driven focus to achieve complex goals, similar to an 'operational order'.

While Novogaia is building a next-gen discovery platform, CEO Tess Bevers emphasizes that the company's primary focus must be advancing its first drug candidates. For early-stage biotechs, the tangible value lies in getting molecules further down the pipeline, not just in perfecting the underlying technology.

Zevra accelerated its transition to a commercial-stage company by acquiring Acer Therapeutics. This strategic move provided a foundational commercial team, specialty pharmacy contracts, and patient advocacy relationships, de-risking their upcoming drug launch by avoiding the distraction of building it all from scratch.

When facing a crisis, Fibrogen's CEO decided to shut down discovery research programs. The value inflection opportunity was too far in the future, and capital was better spent on assets with the potential to create more near-term value, ensuring the company's survival.

While scientific acumen is valuable, the most critical trait for a biotech CEO is perseverance. The role involves weathering constant challenges where everyone—the board, investors, employees—can seem to be against you. An unwavering focus on the patient mission is essential to push through.

A decade ago, Neurocrine made the difficult decision to pause development of a promising CRF2 agonist. This ruthless prioritization freed up essential capital and focus to successfully develop what became INGREZZA, their blockbuster drug, demonstrating a long-term strategy of sacrificing a good opportunity for a great one.

Unlike typical biotechs that grow from Research to Development to Commercial (R-D-C), Zevra is pursuing a 'C to D to R' model. It focuses first on executing commercially and in late-stage development, using that success to become a partner of choice and eventually earn the right to invest in early-stage research.

Benetech’s turnaround is credited to CEO Jarrell Banks, a former investor who drove its gene therapy program forward by solving key issues like regulatory endpoints. His success demonstrates how one dedicated individual can transform a company’s trajectory, a story mirrored at CG Oncology with CEO Arthur Kwan.

When re-architecting the business, the new COO (now CEO) physically boxed up a major drone project to signal a radical shift. This forced the team to focus on doing one thing exceptionally well—building an autonomous platform—before expanding off of that solid base.